this is the REAL BREAD
Signed in BAKER
anons please get behind this bread and post here
also fill in this bread:
Q Research General #13957: Surrender to None ['Digital Battleground']
Never give up the FIGHT!!!
May God bless this bread and all who post upon it
repost:
Trump's Regeneron infusion 'seemed to go through very well,' 'will last a long time,' doctor says
President Trump's physician is treating his coronavirus diagnosis with Regeneron's experimental treatment and his one infusion "seemed to go through very well" and "will last a long time," the company's chief scientific officer explained to "CAVUTO Live" Saturday.
White House physician Dr. Sean Conley and other members of the medical team briefed reporters on Trump’s condition. Conley said they were “extremely happy with the progress” Trump is making.
REGENERON IS TRUMP'S COVID-19 TREATMENT: WHAT TO KNOW
"It's all about beating the virus and so we're just helping the natural immune system beat it, by supplementing it with this antibody cocktail," Dr. George Yancopoulos, the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals, explained to host Neil Cavuto.
Regeneron confirmed it has released the drug under the "Compassionate Use Request" in which the Food & Drug Administration permits usage to those not in clinical trials, according to the Mayo Clinic. Normally, this process is long and challenging…..
https://www.foxnews.com/health/trump-regeneron-antibody-cocktail-treatment-covid-19-dr-george-yancopoulos
Following the SIGNED IN BAKER
is not an appeal to authority
It's a recognition of baker traditions
and all that Q stands for.
help support the kitch
plz post HERE anons
New England Patriots quarterback Cam Newton has tested positive for Covid-19, according to reports from NFL Network and ESPN, which cited league sources.
https://twitter.com/cnnbrk/status/1312464464503992321?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
cnn.com
not sure whether picked up….
The Epoch Times
@EpochTimes
“Tweets that wish or hope for death, serious bodily harm or fatal disease against anyone are not allowed and will need to be removed.”
#Twitter and #Facebook said they would remove posts that wish or hope for President Trump’s death.
https://twitter.com/EpochTimes/status/1312500189194645504
this is from baker of HIJACKED BREAD
WHO IS BAKING THIS FAKE BREAD?
AN "ANON" BAKER
Great to have non-namefag baker, any shill can do.
Regeneron is Trump's COVID-19 treatment: What to know
The biotech powerhouse went public in 1991.
Could an antibody cocktail from Regeneron help President Trump?
Dr. Matt McCarthy, an infectious disease expert, discusses possible treatment options for President Trump after he tested positive for the coronavirus.
President Trump's physician is treating his COVID-19 with Regeneron's experimental treatment. The details were released as the President makes his way to Walter Reed National Military Medical Center for observation.
Regeneron confirmed it has released the drug under the "Compassionate Use Request" in which the Food & Drug Administration permits usage to those, not in clinical trials, according to the Mayo Clinic. Normally, this process is long and challenging.
A year ago, this biotech company was known mainly to health care investors and the medical community now it's on the cusp of potentially treating the millions infected with the coronavirus.
FOX Business has more on the business behind the company.
Regeneron Stock & Financial Performance
The company, which is headquartered in Tarrytown, N.Y., went public in 1991 at $22 per share. Today, the stock is trading around $565 per share, as it races towards a treatment for COVID-19. Regeneron has seven FDA approved drugs and 20 in the pipeline, according to company documents….
https://www.foxbusiness.com/markets/regeneron-is-trumps-covid-19-treatment-what-to-know
The latest on Trump's Covid-19 diagnosis - more on Regeneron
CNN
The White House confirmed doctors gave President Trump a single 8-gram dose of Regeneron’s experimental antibody therapy to treat Covid-19.
Regeneron, a New York-based biotech company, confirmed that it provided the drug in what’s commonly known as a “compassionate use” request from the President’s physicians.
The therapy is known as REGN-COV2; the company calls it a “cocktail” of two monoclonal antibodies.
Polyclonal antibodies are made using several different immune cells, while monoclonal antibodies are made using identical immune cells that are clones of a specific parent cell.
To make its monoclonal antibody therapy, Regeneron scientists selected two antibodies that best neutralized a version of the novel coronavirus in the lab. They then cloned these antibodies and put it into a treatment. Regeneron is using two antibodies since they think it will work best as the virus mutates.
About Regeneron’s Covid-19 antibody therapy trials:
The company started testing the treatment in humans in June. Early trials showed it was safe.
On Tuesday, the company announced results from the first 275 non-hospitalized patients in a late-stage trial that showed that the treatment was safe and seemed to reduce viral levels and improve symptoms in patients with Covid-19. The greatest improvements were seen in patients who hadn’t already mounted a detectable immune response to the novel coronavirus. The patients in the trial were younger than Trump; the average age was 44 years old. More than 40% of the patients were obese, like the President, and a total of 64% of the patients had one or more underlying risk factor for severe Covid-19. The study results have not been peer-reviewed and only topline data was available from the company in a news release.
Outside infectious disease experts said the early results looked “very promising,” but they would need to see results from a larger number of patients.
What’s next:
The company said it is continuing to study this therapy. There will be more data to come from this trial and from a trial involving hospitalized patients and one that is testing the antibody cocktail as prevention for people who have contact with someone in their household who has Covid-19.
Regeneron is in talks with regulators to see if the US Food and Drug Administration would consider an emergency authorization of the drug.
There are at least 70 different antibody treatments for Covid-19 under investigation.
updated 5:26 p.m. ET, October 3, 2020
https://www.cnn.com/politics/live-news/trump-covid-19-updates-saturday/h_572663cbb8d11ac73cf2fe1aba6f72d9
Regeneron.com website
UK BIOBANK LIFE SCIENCES CONSORTIUM
Regeneron and its life science company consortium members are serving as a model for ethical ‘pre-competitive’ collaboration that can accelerate medical discoveries and potentially improve patient care. In 2018, we welcomed collaborators AbbVie, Alnylam, AstraZeneca, Biogen, Bristol-Myers Squibb, Pfizer Inc. and Takeda into a major research consortium to fund the generation of genetic exome sequence data from the 500,000 volunteer participants who make up the UK Biobank health resource. Each collaborator is committing $10 million to enable a dramatic acceleration of sequencing timelines, with Regeneron covering the balance and conducting the sequencing effort. The sequencing data will be paired with detailed, de-identified medical and health records from the UK Biobank resource, including enhanced measures such as brain, heart, and body imaging, to create an unparalleled resource for linking human genetic variations to human biology and disease. This invaluable scientific resource is being made available to the global research community through the UK Biobank’s access process.
Our unique approach and collaboration amongst industry has the potential to dramatically speed up the drug development process. Recent advances in sequencing technology and integration of rich data resources mean there are infinite discoveries to be made that could potentially impact human health. In order to fully tap this new resource, we believe cooperation, transparency, and open access will be absolutely necessary and, more importantly, is the right thing to do.
https://www.regeneron.com/genetics-center
Leadership:
Leonard S. Schleifer, MB, PhD
George D. Yancopouolous, MB, PhD
(more)
https://www.regeneron.com/leadership
Press release on regeneron:
https://investor.regeneron.com/news-releases/news-release-details/regeneron-forms-consortium-leading-life-sciences-companies
Financials:
https://investor.regeneron.com/financial-information
Regeneron "collaborates" with Sanofi-Aventis
from Qresear.ch dig in June 2020:
#1600827 at 2018-06-01 00:30:52 (UTC+1)
Q Research General #2013: Excavations
Not sure if this been dug yet, but the makers of AMBIEN, Sanofi-Aventis has a very interesting history.
>https://infogalactic.com/info/Sanofi#History
Sanofi:
Sanofi was founded in 1973[6] as subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total S.A.), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company.
++Synth�labo__ was founded in 1970 through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834) and Laboratoires Robert & Carri�re (founded in 1899). In 1973, the French cosmetics group L'Or�al acquired the majority of its share capital.
Sanofi-Synth�labo was formed in 1999 when Sanofi merged with Synth�labo. The merged companies focused on pharmaceuticals, divesting several businesses soon after the merger.
Aventis
Aventis was formed in 1999 when French company Rh�ne-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Cassella, Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.
At the time of the merger, Rh�ne-Poulenc's business included the pharmaceutical businesses Rorer, Centeon (blood products), and Pasteur Merieux (vaccines)
Merieux has been in the business of selling blood products, and In the 1980s during the AIDS epidemic, Merieux and other companies were involved in scandals related to HIV-contaminated haemophilia blood products that were sold to developing nations.[12]
Merger : Sanofi-Aventis
Sanofi-Aventis was formed in 2004 when Sanofi-Synth�labo acquired Aventis.
he French government played a strong role, desiring what it called a "local solution", by putting heavy pressure on Sanofi-Synth�labo to raise its bid for Aventis and for Aventis to accept the offer.
One of the largest risks in the deal for both sides, was the fate of the patents protecting Clopidogrel (Plavix) which was one of the top-selling drugs in the world at the time and the major source of Aventis' revenue.
In 2006, Iraqis infected with HIV sued Sanofi and Baxter due to HIV-contaminated haemophilia blood products sold by Merieux in the 1980s.
In 2003 Aventis entered into a collaboration with regeneron, a New York biotechnology company.
In 2007 Sanofi-Aventis expanded on Aventis' prior relationship with regeneron.
Sanofi plans to unload a $13B Regeneron stake. Is a rare disease buyout next?
https://www.fiercepharma.com/pharma/sanofi-sells-13b-holding-regeneron-a-rare-disease-buyout-next
by Eric Sagonowsky | May 26, 2020 9:29am
Paul Hudson has served as Sanofi's CEO since September. (Sanofi)
Sanofi and Regeneron unveiled plans last year to restructure their longstanding partnership, and now there are bigger changes afoot, for Sanofi at least: The French drugmaker aims to sell most of its massive stake in its biotech partner.
Sanofi detailed plans to unload about 22.8 million Regeneron shares, a stake worth some $13 billion.
The sale would put a big chunk of cash into Sanofi's coffers—and at CEO Paul Hudson's disposal for potential dealmaking.
The partnership between the two companies “has been one of the most productive in the industry,” Hudson said in a statement. While Sanofi “remains committed” to their partnership, the company believes “the proceeds from this transaction will help further our ability to execute on our strategy to drive innovation and growth,” Hudson said.
With the proceeds, Sanofi will have some serious M&A spending power that could bolster its oncology resurgence, its rare disease business, or both. It could leverage the cash into deals worth as much as $50 billion, Bloomberg reports.
"We are not surprised by this strategic decision which very much ties in with the group’s story," ODDO analyst Martial Descoutures wrote in a Tuesday investor note, adding, "The question now is what the group intends to do with [the] proceeds."
The ODDO analyst doesn't believe Sanofi will use all the cash to make deals; instead, the company will likely invest in organic growth, too, and steer toward several buys rather than one big one. "[W]e think that Sanofi will maintain its external growth momentum, but with a focus on medium-scale deals," Descoutures wrote, with bolt-on acquisitions worth between $2 billion and $5 billion.
That strategy would fit in with Sanofi's recent buyout of Synthorx, a cancer biotech the company purchased for $2.5 billion in December.
In all, Sanofi now holds 23.2 million shares and plans to keep about 400,000 “in support of the ongoing collaboration with Regeneron.” Regeneron itself agreed to buy $5 billion worth of its own shares. The rest will be subject to a public offering.
The drugmakers have been partners since 2003 and have brought five drugs to market together. Back in December, Sanofi—under new CEO Paul Hudson—moved to restructure the collaboration to zero in on Dupixent, an immunology star with the potential to become a megablockbuster. In results released Friday that could lead to another FDA approval, the drug met two co-primary endpoints in a phase 3 trial in eosinophilic esophagitis.
Under the rejigged partnership, the companies planned to divvy up various rights on PCSK9 drug Praluent and rheumatoid arthritis therapy Kevzara. Since then, Kevzara has gained attention as a possible COVID-19 medicine, so the partners are waiting to see whether it can help patients with novel coronavirus infections.
RELATED: Sanofi beat out 3 suitors and one last-minute bid in its pricey $2.5B Synthorx buyout
RELATED: Sanofi, Regeneron uncouple on long-standing drug partnership, splitting up Praluent, Kevzara
Regeneron: Wikipedia Excerpts
https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988.[4] Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Company history
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
On March 26, 2012, Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. The new drug targets the PCSK9 gene.[5][citation needed]
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[6] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.[7] REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best stock of the 2010s, with a total return of 1,457%.[8]
Regeneron Pharmaceuticals was home to the two highest-paid pharmaceutical executives as of 2020.[9]
During the COVID-19 pandemic, in early 2020, Regeneron made a deal with the US-government Biomedical Advanced Research and Development Authority that the government would fund 80% of the costs for Regeneron to develop and manufacture Coronavirus disease 2019 treatments, and Regeneron would retain the right to set prices and control production. This deal was criticized in the New York Times. Such deals are not unusual for routine drug development in the American pharmaceutical market.[9]
In May 2020 Regeneron announced it would repurchase around $5 billion of its shares, held directly by Sanofi. Prior to the transaction Sanofi held 23.2 million Regeneron shares.[10]
As of September 2020, Regeneron is evaluating an artificial "antibody cocktail", REGN-COV2, for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 coronavirus infection.[11][12][13]
Looks like one of Regeneron's founders got in trouble for saying "all lives matter" in end-of-June speech. Potentially good news, espec. for POTUS.
Regeneron’s Billionaire Cofounder Criticized After ‘All Lives Matter’ Graduation Speech
https://www.forbes.com/sites/leahrosenbaum/2020/06/30/regenerons-billionaire-cofounder-criticized-after-all-lives-matter-graduation-speech/#3d1d0c4a709c
Jun 30, 2020,07:10pm EDT
George Yancopoulos, the billionaire cofounder and Chief Scientific Officer of Regeneron Pharmaceuticals, created a stir over the weekend when he gave a graduation speech at Yorktown High School that touched on the recent murder of George Floyd, and called police “scapegoats” in larger issues of systemic discrimination. Parents and students of the New York suburb took to social media to complain about Yancopoulos’ speech, which was seen as divisive and inappropriate for a high school graduation.
At the end of his speech to graduates at a drive-in ceremony, Yancopoulos said, "I believe Black Lives matter, though I do not think it should be a crime to say, 'All lives matter.'" He continued to say that while police brutality may be a trendy topic today, the police are “convenient scapegoats” of a larger systemic problem. Citing medical data that Black women are more likely to die in childbirth than white women, Yancopoulos said, "that's a lot more innocent deaths than at the hands of the police."
He also said that Black men were more likely to be killed by other Black men. "So if Black lives matter, what about all these Black lives?” he asked the audience. "Widespread hate and prejudice against all cops is just as wrong as hate and prejudice against any race or ethnic group."
Members of the audience began to honk their horns during his speech, which Yancopoulos called “another act of cowardice.”
Yancopoulos, who has a net worth of $1.4 billion dollars, is leading the Tarrytown, NY-based biotech company’s development of treatments for Covid-19. Earlier this month, the company announced the beginning of its first clinical trial of an antibody cocktail aimed at both treating and preventing infection from the disease.
Yorktown superintendent Ron Hattar said in a statement that he believed Yancopoulos would be a good choice for graduation speaker given Regeneron’s efforts to find a treatment for Covid-19, and its close proximity to Yorktown. “However, unexpected comments were made in that address that do not align with the principles of the Yorktown Central School District.”
Meredith Brown, a member of the graduating class of 2020, says that she was furious at the political tone of the speech. "All the students are saying that this is bringing up division,” she says. She also says that as a Black woman, several portions of his speech were hard to hear. "It felt like he was trying to derail from the problem at hand,” she says, “and that was what really hurt me as well."
Another Yorktown High graduating student, Tamara Bashjawish, says that she was “horrified” at the unprofessional nature of Yancopoulos’ speech. “I really hope that Mr. Yancopoulos would apologize to the seniors for making our graduation political and everyone divided,” she says.
After the graduation ceremony, parents and children took to social media to share their thoughts on the speech. While some parents agreed with the message of the speech, they did not think it was an appropriate topic at a high school graduation. Other parents in the school district disagreed with both the timing and the content of the speech. Jeremy Newberger, a film director and father of two children in the Yorktown school district, said that he was upset by the “false equivalency” of Yancopoulos’ speech. "Regeneron is a source of pride in Yorktown," Newberger says, but the statistics that Yancopoulos cited “minimalize what Black people are experiencing” at the hands of police. Plus,”the graduates were hoping to be uplifted and rewarded,” Newberger says, “not alienated by some guy with an axe to grind.”
Several of the statistics that Yancopoulos cited during the speech have recently been found to be inaccurate or misleading. For example, Yancopoulos said that only nine unarmed Black men were killed by police in 2019. Though widely circulated by conservative personalities such as Charlie Kirk and Larry Elder, an investigation from USA Today concluded that the statistic is inaccurate.
The phrase “All lives matter,” which Yancopoulos said in his speech, also engenders a great deal of controversy. Scholars such as Rob Eschmann, an assistant professor at Boston University’s School of Social Work, argue that this and similar phrases contribute to a type of subtle and pervasive racism called “colorblind” racism, where people claim not to see differences between races. “‘All lives matter’ folks want there to continue to be silence about race, they don't want to have to talk about race, and saying ‘all lives matter’ is a way for allowing racist violence against Black folks to continue," Eschmann says.
Yancopoulos is one of several prominent executives that have come under fire in recent weeks for their views on the Black Lives Matter movement. Yancopoulos reportedly told the Westchester Journal News that the aim of his speech was to raise questions about the many issues that need solving beyond police bias. “I apologize if my remarks about these difficult and complex issues deteriorated from the Yorktown High School graduate’s experience,” he said.
This controversy isn’t the only one that Regeneron is facing right now. Last week, the company’s stock plunged after the Department of Justice filed a suit against Regeneron for using a charity foundation to pay “kickbacks” to help patients cover the cost of eye medication Eylea, an allegation that the company denies.
The company did not directly comment on Yancopoulos’ remarks, but in a statement to Forbes, a Regeneron spokesperson wrote, “As a company dedicated to saving and improving human life, Regeneron sees it as an extension of our mission to stand against racial injustice and discrimination of all kinds.”
EU begins legal action against UK after it approves contentious Brexit bill
not in qresear.ch
Key points:
The U.K. has said the Internal Market Bill, which now requires the approval of the House of Lords, will protect the integrity of the U.K.
European Commission President Ursula von der Leyen said the bloc had given Britain until the end of September to remove “problematic parts” of the bill, but the deadline has now lapsed and the provisions remained.
The EU had previously said the proposed legislation would constitute an “extremely serious violation” of the withdrawal agreement.
LONDON — European Commission President Ursula von der Leyen said Thursday it has formally notified the U.K. over its contentious plan to override the Brexit divorce deal, marking the first step in legal proceedings.
The notification came after U.K. lawmakers approved Prime Minister Boris Johnson’s Internal Market Bill earlier this week, despite some ministers admitting the legislation could lead to the country breaching international law.
The U.K. has said the proposed legislation, which now requires the approval of the House of Lords, will protect the integrity of the U.K. The bill would allow ministers to unilaterally amend elements of the country’s withdrawal agreement with the EU.
It has amplified divisions between the U.K. and Europe, threatening to scupper trade talks during the post-Brexit transition period.
“If adopted as is, it will be in full contradiction to the protocol of Ireland-Northern Ireland,” von der Leyen said in a televised statement.
The head of the EU’s executive arm said it had given Britain until the end of September to remove “problematic parts” of the Internal Market Bill, but the deadline has now lapsed and the provisions remained.
What is the Internal Market Bill?
The Internal Market Bill would grant the British government powers to not consult the EU in state aid cases involving the trade of goods between Northern Ireland and the rest of the EU. The U.K. had agreed to do the opposite when signing its divorce deal with the EU in January.
The bill could also change requirements that Northern Irish firms complete export summary declarations when shipping goods to the mainland.
The dispute has prompted some analysts to suggest the U.K. and EU will ultimately fail to reach a trade agreement.
The absence of a deal before the end of the year would see the U.K. trade with the EU on World Trade Organization rules. This would mean higher costs and barriers for businesses on both sides of the English Channel, when compared with the current system.
https://www.cnbc.com/2020/10/01/eu-begins-legal-action-against-the-uk-after-it-approves-controversial-brexit-bill.html